A detailed history of Soleus Capital Management, L.P. transactions in Celcuity Inc. stock. As of the latest transaction made, Soleus Capital Management, L.P. holds 1,731,338 shares of CELC stock, worth $27.4 Million. This represents 3.06% of its overall portfolio holdings.

Number of Shares
1,731,338
Previous 2,179,481 20.56%
Holding current value
$27.4 Million
Previous $31.8 Million 17.76%
% of portfolio
3.06%
Previous 4.09%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$13.74 - $21.6 $6.16 Million - $9.68 Million
-448,143 Reduced 20.56%
1,731,338 $37.4 Million
Q4 2023

Feb 14, 2024

BUY
$8.7 - $15.02 $1.07 Million - $1.85 Million
122,997 Added 5.98%
2,179,481 $31.8 Million
Q3 2023

Nov 14, 2023

BUY
$8.96 - $10.75 $1.19 Million - $1.43 Million
133,201 Added 6.93%
2,056,484 $18.8 Million
Q2 2023

Aug 14, 2023

BUY
$9.39 - $12.18 $2.21 Million - $2.87 Million
235,350 Added 13.94%
1,923,283 $21.1 Million
Q1 2023

May 15, 2023

BUY
$9.4 - $12.82 $4.49 Million - $6.12 Million
477,705 Added 39.47%
1,687,933 $17.3 Million
Q4 2022

Feb 14, 2023

BUY
$7.55 - $14.01 $5.79 Million - $10.7 Million
766,316 Added 172.63%
1,210,228 $17 Million
Q3 2022

Nov 14, 2022

BUY
$8.0 - $10.64 $200,000 - $266,000
25,000 Added 5.97%
443,912 $4.46 Million
Q2 2022

Aug 15, 2022

BUY
$5.35 - $10.11 $2.07 Million - $3.91 Million
386,839 Added 1206.12%
418,912 $3.81 Million
Q4 2021

Feb 14, 2022

SELL
$11.96 - $19.35 $617,315 - $998,750
-51,615 Reduced 61.68%
32,073 $423,000
Q3 2021

Nov 15, 2021

SELL
$17.35 - $24.87 $1.41 Million - $2.02 Million
-81,136 Reduced 49.23%
83,688 $1.51 Million
Q2 2021

Aug 16, 2021

BUY
$14.25 - $30.93 $2.35 Million - $5.1 Million
164,824 New
164,824 $3.96 Million

Others Institutions Holding CELC

About Celcuity Inc.


  • Ticker CELC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 14,941,300
  • Market Cap $236M
  • Description
  • Celcuity Inc., a clinical stage biotechnology company, focuses on the development of molecularly targeted therapies for cancer patients in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therap...
More about CELC
Track This Portfolio

Track Soleus Capital Management, L.P. Portfolio

Follow Soleus Capital Management, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Soleus Capital Management, L.P. with notifications on news.